Early use of realgar-indigo naturalis formula plus ATRA for APL patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether giving a combination of two oral medicines—realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA)—early in treatment can help people with acute promyelocytic leukemia (APL), a specific type of blood cancer. The goal is to see if this approach works better than current standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have been diagnosed with acute promyelocytic leukemia (APL), a specific type of blood cancer confirmed by bone marrow tests.
- You cannot have another type of leukemia or a different active cancer.
- Your liver, kidneys, and heart must be working well enough (no severe damage).
- You cannot be pregnant or breastfeeding if you are a woman.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an oral version of arsenic trioxide works as well as the IV version for people with a certain type of leukemia called APL. It aims to confirm that taking the drug by mouth has similar safety and effectiveness.
This trial studies chidamide and venetoclax in people with a specific type of acute promyelocytic leukemia (APL) that has not responded to standard treatment with all-trans retinoic acid (RA) plus arsenic. It may help by testing a new combination for cases in “non-remission” status.
This trial tests a combination of oral arsenic and ATRA for people newly diagnosed with acute promyelocytic leukemia (APL). It aims to see if this drug combo can treat the disease effectively without standard chemotherapy.
This study looks at how well first-time treatment with ATO plus ATRA works in adults with acute promyelocytic leukemia (APL). It mainly checks treatment results in real life, including whether patients reach “molecular remission” (very deep disease control).
This trial studies how well a combination of tretinoin (ATRA) and arsenic trioxide (ATO)—with or without another antibody-like drug called gemtuzumab—treats people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if these medicines work better together and are safe.
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
Hear when a new APL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.